CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 16, 2019
Result type: Reports
Project Number: SR0579-000
Product Line: Reimbursement Review

Generic Name: buprenorphine

Brand Name: Sublocade

Manufacturer: Indivior Canada Ltd.

Therapeutic Area: Opioid use disorder, treatment

Indications: Opioid use disorder, treatment

Manufacturer Requested Reimbursement Criteria1: For the treatment of moderate-to-severe opioid use disorder in adults. Sublocade should be used as part of a complete treatment plan that includes counseling and psychosocial support.

Submission Type: Initial

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: June 19, 2019

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input posted July 25, 2018
Patient group input closed September 14, 2018

- No patient input submission received

Submission received December 20, 2018
Submission accepted for review January 11, 2019
Review initiated January 14, 2019
Draft CADTH review report(s) sent to applicant March 28, 2019
Comments from applicant on draft CADTH review report(s) received April 08, 2019
Redaction requests from applicant on draft CADTH review report(s) received April 15, 2019
CADTH review team's comments on draft CADTH review report(s) sent to applicant May 03, 2019
Canadian Drug Expert Committee (CDEC) meeting May 15, 2019
CDEC recommendation & redacted CADTH review report(s) sent to applicant and drug plans May 29, 2019
Embargo period ended and validation of redacted CADTH review report(s) received June 12, 2019
CDEC Final Recommendation issued to applicant and drug plans June 19, 2019
CDEC Final Recommendation posted June 21, 2019
Final CADTH review report(s) posted July 16, 2019